Eupraxia Pharmaceuticals (NASDAQ:EPRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) from a strong sell rating to a sell rating in a research note issued to investors on Saturday,Wall Street Zen reports.

A number of other brokerages have also weighed in on EPRX. Oppenheimer reissued an “outperform” rating on shares of Eupraxia Pharmaceuticals in a report on Tuesday, October 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 15th. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 8th. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research note on Thursday, October 1st. Finally, Stifel Nicolaus set a $25.00 price target on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.80.

Eupraxia Pharmaceuticals Trading Down 1.0%

NASDAQ:EPRX opened at $6.76 on Friday. Eupraxia Pharmaceuticals has a twelve month low of $5.25 and a twelve month high of $9.32. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.00 and a quick ratio of 16.00. The company’s 50 day moving average is $7.59 and its two-hundred day moving average is $7.31.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. On average, sell-side analysts expect that Eupraxia Pharmaceuticals will post -0.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. increased its stake in shares of Eupraxia Pharmaceuticals by 28.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 16,000 shares of the company’s stock worth $133,000 after acquiring an additional 3,500 shares during the period. Persistent Asset Partners Ltd purchased a new position in shares of Eupraxia Pharmaceuticals during the second quarter worth $25,000. AXQ Capital LP raised its holdings in shares of Eupraxia Pharmaceuticals by 34.2% during the second quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock worth $140,000 after purchasing an additional 5,390 shares during the last quarter. BlackRock Inc. acquired a new position in Eupraxia Pharmaceuticals during the second quarter valued at $40,000. Finally, Bank of America Corp DE lifted its position in Eupraxia Pharmaceuticals by 5.9% during the first quarter. Bank of America Corp DE now owns 268,221 shares of the company’s stock valued at $1,942,000 after purchasing an additional 14,900 shares during the period.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a Canadian clinical-stage biopharmaceutical company focused on developing locally delivered therapies for chronic diseases. The company uses its proprietary DiffuSphere technology to formulate drug products designed to provide controlled, sustained release at targeted sites in the body, with the goal of improving treatment effectiveness and tolerability.

Eupraxia’s lead development program, EP-262, is an intra-articular therapy being developed for osteoarthritis of the knee.